Cantor Fitzgerald Estimates GPCR FY2025 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Structure Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will earn ($1.09) per share for the year. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share.

Several other research firms have also recently weighed in on GPCR. William Blair initiated coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating on the stock. HC Wainwright lowered their price objective on shares of Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Monday, May 12th. Finally, Citigroup initiated coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They set a “buy” rating and a $60.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $76.50.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $21.83 on Tuesday. The firm’s fifty day moving average price is $22.18 and its 200-day moving average price is $24.86. The stock has a market cap of $1.25 billion, a P/E ratio of -29.50 and a beta of -1.87. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $54.08.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03).

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in GPCR. Deep Track Capital LP grew its holdings in shares of Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock valued at $75,936,000 after purchasing an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after purchasing an additional 575,000 shares during the last quarter. Boxer Capital Management LLC bought a new position in shares of Structure Therapeutics during the 4th quarter valued at $13,560,000. Marshall Wace LLP grew its holdings in shares of Structure Therapeutics by 339.6% during the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company’s stock valued at $15,817,000 after purchasing an additional 450,531 shares during the last quarter. Finally, Foresite Capital Management VI LLC bought a new position in shares of Structure Therapeutics during the 4th quarter valued at $11,390,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.